This study is designed to look at pharmacogenomic (PGx) profiles in 50 allogeneic blood and marrow transplant (BMT) patients at the onset of the transplant process and assess whether potential genomic mutations affect their individual drug metabolism, impacting morbidity and mortality. We specifically looked at the CYP3A5 variants to determine variation in calcineurin inhibitor metabolism and the SLCO1B1 variants to determine variation in effects of methotrexate toxicity

Mary Thoma, Kimberly Langer, Patricia McLean, David Dingli

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'This study is designed to look at pharmacogenomic (PGx) profiles in 50 allogeneic blood and marrow transplant (BMT) patients at the onset of the transplant process and assess whether potential genomic mutations affect their individual drug metabolism, impacting morbidity and mortality. We specifically looked at the CYP3A5 variants to determine variation in calcineurin inhibitor metabolism and the SLCO1B1 variants to determine variation in effects of methotrexate toxicity'. Together they form a unique fingerprint.

Medicine & Life Sciences